In Vivo and In Vitro Diagnostics Converge: Siemens buys DPC
Executive Summary
Why would imaging giant Siemens buy traditional in vitro diagnostics firm Diagnostic Products for $1.86 billion? Siemens has a mature imaging business, so the high growth opportunities in diagnostics, with their recurring revenue streams from consumables, look attractive. But more than that, it's becoming apparent that on the molecular level, in vivo imaging and in vitro diagnostics are converging.You may also be interested in...
The Digital Pathology Revolution: Breaking the Glass Ceiling
Acquisitions in 2007: Medical Device Companies Regroup
Trends for the New Year: Can Medtech Build on the Success of 2007?
Need a specific report? 1000+ reports available
Buy Reports